Equities Analysts Offer Predictions for ORIC Q3 Earnings

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) – Equities researchers at HC Wainwright upped their Q3 2025 earnings estimates for shares of Oric Pharmaceuticals in a report issued on Thursday, August 14th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.38) for the quarter, up from their previous estimate of ($0.46). HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Oric Pharmaceuticals’ current full-year earnings is ($2.17) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals’ Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.60) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.51) EPS.

Several other brokerages have also recently weighed in on ORIC. Zacks Research upgraded Oric Pharmaceuticals to a “hold” rating in a research note on Tuesday, August 12th. JPMorgan Chase & Co. dropped their price objective on Oric Pharmaceuticals from $20.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday. Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Oric Pharmaceuticals in a research note on Monday, June 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Guggenheim restated a “buy” rating and set a $18.00 price objective on shares of Oric Pharmaceuticals in a research note on Wednesday, August 13th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.63.

Oric Pharmaceuticals Trading Down 2.7%

Shares of NASDAQ:ORIC opened at $9.66 on Monday. The stock’s fifty day simple moving average is $10.30 and its two-hundred day simple moving average is $8.06. Oric Pharmaceuticals has a 1-year low of $3.90 and a 1-year high of $14.67. The stock has a market cap of $938.18 million, a PE ratio of -5.11 and a beta of 1.69.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01).

Institutional Investors Weigh In On Oric Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its stake in shares of Oric Pharmaceuticals by 1,293.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,757 shares of the company’s stock worth $119,000 after purchasing an additional 10,913 shares during the period. Eventide Asset Management LLC bought a new stake in Oric Pharmaceuticals in the 2nd quarter valued at about $9,657,000. BNP Paribas Financial Markets raised its stake in Oric Pharmaceuticals by 1,102.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 86,755 shares of the company’s stock valued at $881,000 after acquiring an additional 79,540 shares during the period. Brevan Howard Capital Management LP bought a new stake in Oric Pharmaceuticals in the 2nd quarter valued at about $352,000. Finally, Bank of America Corp DE raised its stake in Oric Pharmaceuticals by 14.9% in the 2nd quarter. Bank of America Corp DE now owns 298,442 shares of the company’s stock valued at $3,029,000 after acquiring an additional 38,641 shares during the period. 95.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Oric Pharmaceuticals news, Director Angie You bought 26,597 shares of the stock in a transaction dated Friday, June 20th. The shares were bought at an average cost of $9.39 per share, for a total transaction of $249,745.83. Following the purchase, the director directly owned 26,597 shares of the company’s stock, valued at approximately $249,745.83. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Dominic Piscitelli sold 32,466 shares of Oric Pharmaceuticals stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total value of $340,893.00. Following the sale, the chief financial officer owned 68,317 shares in the company, valued at $717,328.50. The trade was a 32.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,000 shares of company stock worth $416,289 over the last quarter. Company insiders own 5.55% of the company’s stock.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.